PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (113)	7/11/1998 2:36:00 PM
From: Timothy Kross	Read Replies (2) of 626

To: All From: Tim I just received the 1997 annual report from Titan Pharmaceutical in the mail. One little tidbit seemed very interesting to me. Novartis has worldwide rights to iloperidone but Titan kept the rights to Japan for themselves. If iloperidone makes it, then that should be quite a market. Japan has 125,000,000 people. Let's assume that 1% have schizophrenia. That makes a market of 1.25 million people with schizophrenia in Japan. Let's say that iloperidone grabs a 20% share of the market. That's 250,000 people in Japan that could be on iloperidone. Let's say they make $500 per year per patient. If these estimates ever do come true, then that's $ 125 million per year profits to Titan Pharmaceuticals just on the schizophrenia market in Japan. Any of these assumptions could be off. I have tried to make my estimates on the conservative side. One thing is sure, the Japanese are a rich nation. Its people sure would be able to afford the new generation serotonin dopamine antipsychotics, and they would probably prefer these newer agents to the older generation phenothiazines which have a much higher side effect profile.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next